Skip to main content

Table 1 Inclusion criteria

From: A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan

nmCRPC

mCRPC

mCNPC patients

Consecutive increases in PSA levels, three times with a minimum one-week interval with the last PSA > 2 ng/mL while minimal initial PSA level of ≥ 1 ng/mL or last PSA level of > 2 ng/mL during first-line medical castration

Consecutive increases in PSA levels, three times with a minimum one-week interval with the last PSA level of > 2 ng/mL while minimal initial PSA level of ≥ 1 ng/mL, or during first-line medical castration with the last PSA level of > 2 ng/mL

Had a confirmed diagnosis of metastatic cancer on or after the confirmed diagnosis of the PC

Had no record of metastatic cancer on or before the index date

Any record of metastatic cancer on or before the index date

Had any record of first-line surgical or medical castration on or after the diagnosis of prostate cancer and metastasis diagnosis (i.e. neither medical nor surgical castrations before the diagnosis of metastasis)

  1. PC Prostate cancer, PSA Prostate-specific antigen, mCRPC Metastatic castration-resistant prostate, nmCRPC Non-metastatic castration-resistant prostate cancer, ng nanogram, mCNPC Metastatic castration-naïve prostate cancer, mL milliliter